Prototypical Stressors

Showing 101 to 125 of 871 Prototypical Stressors

ID	Prototypical Stressor Name	Associated Chemical(s): Name, CAS-RN, DTXSID	Associated AOPs

360	Ethanol	Ethanol, CAS-RN: 64-17-5, DTXSID9020584	2 AOPs 260: CYP2E1 activation and formation of protein adducts leading to neurodegeneration 436: Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries
261	Tetrabromobisphenol A	3,3',5,5'-Tetrabromobisphenol A, CAS-RN: 79-94-7, DTXSID1026081	2 AOPs 152: Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity 504: SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level
367	Diuron	Diuron, CAS-RN: 330-54-1, DTXSID0020446	2 AOPs 335: AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment 567: Binding to plastoquinone B site leading to decreased population growth rate via photosystem II inhibition
256	Polychlorinated dibenzodioxins		2 AOPs 152: Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity 150: Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF
255	Graphene oxide nanoparticles		2 AOPs 210: Activation of c-Jun N-terminal kinase (JNK) and Forkhead box O (FOXO) and reduction of WNT pathways leading to reproductive failure: Integrated multi-OMICS approach for AOP building 237: Substance interaction with lung resident cell membrane components leading to atherosclerosis via acute phase response
768	PCB 126		2 AOPs 458: AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals 459: AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals
443	Decitabine	Decitabine, CAS-RN: 2353-33-5, DTXSID7030432	2 AOPs 290: Mitochondrial ATP synthase antagonism leading to growth inhibition (1) 291: Mitochondrial ATP synthase antagonism leading to growth inhibition (2)
706	Terfenadine	Terfenadine, CAS-RN: 50679-08-8, DTXSID2023642	2 AOPs 519: Cardiac ion channels blockade leading to increased incidence of cardiovascular morbidity and mortality 555: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure
707	Cisapride	Cisapride, CAS-RN: 81098-60-4, DTXSID3022825	2 AOPs 519: Cardiac ion channels blockade leading to increased incidence of cardiovascular morbidity and mortality 555: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure
203	Fluvoxamine	Fluvoxamine, CAS-RN: 54739-18-3, DTXSID2044002	2 AOPs 195: 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline
208	Gemfibrozil	Gemfibrozil, CAS-RN: 25812-30-0, DTXSID0020652	2 AOPs 37: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents 323: PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone
721	Manganese	Manganese, CAS-RN: 7439-96-5, DTXSID2024169	2 AOPs 499: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release 500: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis
211	Fenofibrate	Fenofibrate, CAS-RN: 49562-28-9, DTXSID2029874	2 AOPs 37: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents 323: PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone
391	Ciprofloxacin	Ciprofloxacin, CAS-RN: 85721-33-1, DTXSID8022824	2 AOPs 144: Endocytic lysosomal uptake leading to liver fibrosis 559: Inhibition of acetylcholinesterase (AChE) leading to arrhythmias
388	Diltiazem	(+)-Diltiazem, CAS-RN: 42399-41-7, DTXSID9022940	2 AOPs 261: L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility 552: Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP)
386	Nimodipine	Nimodipine, CAS-RN: 66085-59-4, DTXSID5023370	2 AOPs 261: L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility 552: Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP)
378	Virus		2 AOPs 237: Substance interaction with lung resident cell membrane components leading to atherosclerosis via acute phase response 374: Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis
248	RH-5849		2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
243	Chromafenozide	Chromafenozide, CAS-RN: 143807-66-3, DTXSID4057976	2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
242	Ponasterone A	Ponasterone A, CAS-RN: 13408-56-5, DTXSID0040595	2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
241	20-hydroxyecdysone	20-Hydroxyecdysone, CAS-RN: 5289-74-7, DTXSID5040388	2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
238	Methoxyfenozide	Methoxyfenozide, CAS-RN: 161050-58-4, DTXSID3032628	2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
383	Amlodipine	Amlodipine, CAS-RN: 88150-42-9, DTXSID7022596	2 AOPs 261: L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility 552: Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP)
382	Nifedipine	Nifedipine, CAS-RN: 21829-25-4, DTXSID2025715	2 AOPs 261: L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility 552: Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP)
444	Sinefungin	Sinefungin, CAS-RN: 58944-73-3, DTXSID10207689	2 AOPs 290: Mitochondrial ATP synthase antagonism leading to growth inhibition (1) 291: Mitochondrial ATP synthase antagonism leading to growth inhibition (2)